The Women’s Health Capital Call will support collaborative projects that aim to improve the discovery, technical innovation, and/or analysis of datasets to answer pressing life science questions around women’s health.
Up to $6 million capital dollars is available for the current program round, with each award anticipated to be approximately $750,000 to support data generation and equipment at not-for-profit partners. Project teams should comprise of not-for-profit Massachusetts institutions collaborating with at least one for-profit Massachusetts life science company to solve a pressing life science question that solely, disproportionately, or differently affects women.
Eligibility & Evaluation
The application period is now closed.
Applicants must be a Massachusetts legally organized “not-for-profit” entity such as an academic/research institution, a hospital engaged in research, business incubator or accelerator, or other not-for-profit entity that would be eligible for capital funding from the Commonwealth of Massachusetts. Institutions that are exclusively health care providers and/or requests for the purchase of equipment associated with standard healthcare delivery would not be eligible for capital funding.
Eligible applicants must meet the following criteria:
- Applicants must be non-profit institutions, including research institutions and academic medical centers.
- A Project Team, consisting of a principal investigator (PI) at Applicant institution and one (or more) Companies must submit each application.
- The PI must have a full-time or part-time faculty position at a college, university, or non-profit institute in Massachusetts. The lead Company must have a presence and be registered to do business in the Commonwealth of Massachusetts.
- The requested funding must support the performance of translational research with an intention to accelerate the understanding of critical healthcare issues or develop new treatment methods for conditions, that solely or disproportionately affect women, or have a different presentation between genders (i.e. heart attacks). The only use allowed of requested funds is toward the support of capital costs (equipment, supplies, reagents, etc.) at the Massachusetts non-profit institution.
- Projects will be evaluated, in part, based on the level of support offered to the Applicant in a support letter(s) which delineates the amount of cash, in-kind, and/or other contributions (equipment donation, cell lines, drug or material samples, internal salary, etc.) to be provided by the Company and any other sources (grantee institution, etc.). The more MLSC dollars leveraged by additional third party support, the stronger the application.
- In addition, the Applicant will be required to provide documentation of a cash component from the Company to support at least one new scientist for the duration of the project following grant award.
- Applicants must demonstrate how they will work collaboratively with the Company to execute the project.
- The intention of these funds is to catalyze new life science discoveries. Therefore, there will be no consideration of sponsored research agreements (or other similar arrangements) executed before January 23, 2020 between the parties as part of the letter of support for this program.
- The Applicant and Company must comply with all other Center agreements, if any.
An external panel of scientists from academia and industry with expertise in women’s wealth will review applications in the following categories:
- Qualifications of the Team
- Use of funds and value to the Massachusetts ecosystem
- Proposed plan, including the following: unmet need/market opportunity, data generation and sharing (if applicable), scientist training, and approach to solving a key question in women’s health
There may be a request of top applicants to meet with our review panel. Those applicants will receive a notification of that request.
Please view the full list of eligibility requirements and evaluation process.
Impact on the Ecosystem
Massachusetts recognizes there has been a lack of development in novel solutions to treat conditions that solely or disproportionately affect women or have a different presentation between genders. This impacts not only patients, but also employers and the healthcare system. The consequences are profound, with women more likely to have adverse drug reactions than men, and the lack of effective therapies results in reduced quality of life. Mass Life aims to support and incentivize translational project teams who are developing novel solutions in this area of need.
Connect with us to Learn More
If you have any questions regarding the application process, e-mail: WomensHealth@Masslifesciences.com.